BIOMARIN PHARMACEUTICAL INC Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
BIOMARIN PHARMACEUTICAL INC (BMRN) had Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High of $160.00 million as of 2015-01-29, per its 10-Q filed 2015-05-05.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh · last filed 2015-05-05
- 2015-01-29: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $160.00M.
| Period end | Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|---|---|
| 2015-01-29 | $160.00M 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |